TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10359886
Drug: AA-2414 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA-2414 (80 mg/day)
Study: 7732331
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg at bedtime)
Study: 1695449
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA, Aspirin) challenge
Study: 108734
Drug: Intravenous THC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous THC, 30‐‐44.8 microgram/kg
Study: 108734
Drug: Combined autonomic
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined autonomic blockade (i.v. saline, 0.04 mg/kg atropine sulfate, 0.2 mg/kg propranolol, or both)
Study: 31786980
Drug: Serum urate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum urate level ≥6.8 mg/dL (hyperuricemia)
Study: 31786980
Drug: Serum urate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum urate level 6.0 to <6.8 mg/dL
Study: 31786980
Drug: Apparent treatment-resistant
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apparent treatment-resistant hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg on 3 antihypertensive medications or use of ≥4 antihypertensive medications)
Study: 31786980
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of antihypertensive medication classes
Study: 31786980
Drug: Serum urate
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum urate level <6.0 mg/dL (reference)
Study: 20473950
Drug: Solar vitamin
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solar vitamin D effective UV radiation (VD dose)
Study: 19049753
Drug: ET‐AR antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐AR antagonist (sitaxsentan) 1 mg/kg
Study: 19049753
Drug: ET‐AR antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐AR antagonist (sitaxsentan) higher doses
Study: 19049753
Drug: ET‐AR antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET‐AR antagonist (sitaxsentan)
Study: 26703220
Drug: Metformin 500mg
Normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg twice daily
Study: 26703220
Drug: Ethinyl estradiol-cyproterone
Normalized name: cyproterone / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl estradiol-cyproterone acetate for 21 days followed by 7 days drug-free
Study: 24673793
Drug: Walnuts (28.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (28.4 g, 6/week)
Study: 15802405
Drug: Unopposed transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed transdermal estradiol (14 microg per day)
Study: 12161495
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg daily with fatty liver (group C)
Study: 12161495
Drug: Tamoxifen 40
Normalized name: tamoxifen 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 40 mg daily without fatty liver (group B)
Study: 10210764
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron 1 mg twice a day on day 1, followed by metoclopramide 60 mg on day 2 and 3
Study: 10210764
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 8 mg on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3
Study: 10210764
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron followed by metoclopramide
Study: 10210764
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus oral ondansetron
Study: 1945205
Drug: Topical dihydrotestosterone
Normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical dihydrotestosterone
Study: 31778823
Drug: GB001 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB001 20 mg
Study: 27041692
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide plus G-CSF (Arm A)
Study: 27041692
Drug: G-CSF alone
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF alone (Arm B)
Study: 16330684
Drug: Candesartan at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan at a target dose of 32 mg once daily
Study: 10458211
Drug: Carboplatin at
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin at 100 mg/m2/wk concurrent with radiation therapy
Study: 7597774
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (0.5 ml, 10 micrograms HBsAg)
Study: 7597774
Drug: Plasma-derived vaccine
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma-derived vaccine (0.5 ml, 25 micrograms HBsAg)
Study: 7597774
Drug: Yeast-derived recombinant
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived recombinant hepatitis B vaccine (0.5 ml, 10 micrograms HBsAg)
Study: 7597774
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B (0.5 ml)
Study: 6805026
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CERM 3726
Study: 6805026
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg CERM 3726
Study: 6805026
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg CERM 3726
Study: 30427054
Drug: Midlateral subacromial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midlateral subacromial injection
Study: 30427054
Drug: Posterior subacromial
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior subacromial injection
Study: 27943533
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for anorexia nervosa (AN)
Study: 22738209
Drug: 200-ml sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-ml sports drink with 1 g of GABA (trial G)
Study: 22738209
Drug: 200-ml sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-ml sports drink without GABA (trial C)
Study: 20035589
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) treatment for 6 months
Study: 9722799
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS) 200 microgram once daily
Study: 9722799
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS) plus loratadine
Study: 9722799
Drug: Placebo (aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (aqueous nasal spray plus tablet)
Study: 9722799
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FP ANS)
Study: 2527121
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (oral, 1 g once daily)
Study: 2527121
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (intravenous, 500 mg in 100 ml of physiological saline)
Study: 415478
Drug: Cyclophosphamide, vincristine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, vincristine, prednisone, and doxorubicine or VM 26 (induction chemotherapy course for 15-20 days)
Study: 415478
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment with cyclophosphamide, vincristine, and prednisone only
Study: 31163332
Drug: MI‐CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI‐CBT plus treatment as usual (TAU)
Study: 28433465
Drug: Carbohydrate-rich beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich beverage (440 kcal/300 mL)
Study: 28433465
Drug: Fat-rich beverage
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-rich beverage (440 kcal/300 mL)
Study: 17722521
Drug: Silicon gel
DrugBank: Silicon (DB12982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicon gel sheet alone
Study: 17722521
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of onion extract and silicon gel sheet
Study: 10091203
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg once daily for 1 year)
Study: 7529520
Drug: Aprotinin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1 x 10(6) kallikrein inactivator units (KIU) as an intravenous bolus and 1 x 10(6) KIU added to the pump prime)
Study: 29488152
Drug: DS-8500a 25
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 25 mg
Study: 29071087
Drug: DS-8500a 75
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 75 mg
Study: 26310621
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) 15 mg/kg body weight
Study: 26310621
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% sodium chloride solution)
Study: 23538970
Drug: venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine ER (75‐300 mg/day)
Study: 23538970
Drug: fluoxetine (20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine (20‐60 mg/day)
Study: 21282194
Drug: Clade 1
Normalized name: INFLUENZA A VIRUS A/VIETNAM/1203/2004 (H5N1, CLADE 1) ANTIGEN (FORMALDEHYDE INACTIVATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clade 1 HA vaccine followed by clade 2 HA vaccine
Study: 21282194
Drug: Schedule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule of injections at days 0 and 14
Study: 21282194
Drug: Schedule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule of injections at days 0 and 28
Study: 21282194
Drug: Schedule of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule of injections at days 0 and 6 months
Study: 19058584
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin (500 mg bid)
Study: 12663340
Drug: 10 parts
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 parts per million (ppm) inhaled nitric oxide (NO)
Study: 11002377
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g plant stanols at lunch
Study: 11002377
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g plant stanols divided over three meals (0.42 g at breakfast, 0.84 g at lunch, 1.25 g at dinner)
Study: 11002377
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g plant stanols divided over three meals
Study: 9296243
Drug: Zafirlukast (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (oral administration)
Study: 9296243
Drug: Zafirlukast (aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast (aerosol dosing)
Study: 27733396
Drug: FeSO4 (∼8
Approvals — FDA: no, EMA: no, PMDA: no
Description: FeSO4 (∼8 mg Fe)
Study: 27733396
Drug: NaFeEDTA (∼8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaFeEDTA (∼8 mg Fe, ∼41 mg EDTA)
Study: 27733396
Drug: Na2EDTA (∼41
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na2EDTA (∼41 mg EDTA)
Study: 12797340
Drug: Budesonide 128
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide 128 g/day
Study: 10836006
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment for noncomplicated colon and rectal cancer
Study: 10836006
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for colon adenocarcinoma and rectal cancer
Study: 10836006
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for complicated colorectal cancer
Study: 31795035
Drug: Escitalopram or
Normalized name: escitalopram Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram or Sertraline (females only)
Study: 25099201
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of risperidone or olanzapine (dose reduced by 50%)
Study: 17488138
Drug: Community pharmacist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community pharmacist-led medicines management service
Study: 15258006
Drug: Dronabinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (10 mg daily)
Study: 11236522
Drug: Haemodialysis for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodialysis for 2-3 hours, started as early as possible after administration of CM (106 +/- 25 minutes)
Study: 30536713
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment after 3 years of zoledronic acid
Study: 24188204
Drug: Budesonide 100
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 100 μg plus oral procaterol 25 μg
Study: 24188204
Drug: Budesonide 100
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 100 μg plus placebo
Study: 11293640
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg, four times daily for 10 days)
Study: 11293640
Drug: Co-amoxiclav (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (325 mg, four times daily for 10 days)
Study: 30783649
Drug: All antiretroviral
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antiretroviral drugs
Study: 25940060
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy plus plantar fascia-specific stretching (Group 2, n = 79)
Study: 25940060
Drug: Radial shock
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial shock wave therapy alone (Group 1, n = 73)
Study: 22030569
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with retractable fixed syringes and needles
Study: 22030569
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections with no needles combined
Study: 22030569
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections with retractable fixed syringes and needles
Study: 22030569
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections with no needles combined
Study: 17614027
Drug: Running with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Running with ingestion of a 4 % glucose solution (GLU)
Study: 16941885
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser treatment
Study: 14550821
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg everolimus twice daily
Study: 14550821
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg everolimus twice daily
Study: 8823459
Drug: 100 IU
Normalized name: Vitamin E 100 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU per kg of rHuEPO subcutaneously twice a week for 2 weeks
Study: 1389934
Drug: Amitriptyline (10-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10-50 mg a day)
Study: 1389934
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (0.28 mg kg-1)
Study: 1389934
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone (0.14 mg kg-1)
Study: 22327097
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive behaviour therapy (CCBT)
Study: 16108749
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with bupivacaine 1 mL/kg after anesthetic induction
Study: 16108749
Drug: Diclofenac suppository
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac suppository 3 mg/kg postinduction and local anesthetic infiltration at port sites
Study: 11167952
Drug: 200 microg
Normalized name: Digoxin 200 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microg intranasal mometasone furoate (MF) once daily
Study: 11167952
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral montelukast plus 10 mg oral cetirizine once daily (MON/CZ)
Study: 9552083
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (HRT + etidronate)
Study: 9552083
Drug: HRT, etidronate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT, etidronate, combined therapy
Study: 2845694
Drug: Edrophonium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.5 mg/kg
Study: 2845694
Drug: Neostigmine 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.04 mg/kg
Study: 29426304
Drug: modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified directly observed therapy
Study: 29426304
Drug: group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: group treatment
Study: 29426304
Drug: self‐administered individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered individual treatment (control)
Study: 25082830
Drug: Novel nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel nicotine inhaler device (0.45 mg and 0.67 mg)
Study: 25082830
Drug: Nicorette® Inhalator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorette® Inhalator (10 mg)
Study: 24277401
Drug: Clean liquid
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [ServClean Liquid Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clean liquid integral protein diet for 3 days before operation without mechanical bowel preparation
Study: 24277401
Drug: Traditional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional diet and mechanical bowel preparation
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for patients with type 1 diabetes
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for patients with type 2 diabetes
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for patients with schizophrenia
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for patients with epilepsy
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for retired patients
Study: 21515531
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy recommendation for unemployed patients
Study: 17690160
Drug: 1170 CC
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1170 CC genotype
Study: 14727937
Drug: roxifiban (DMP754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxifiban (DMP754) 2 mg/day
Study: 14727937
Drug: roxifiban (DMP754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxifiban (DMP754) 2.5 mg/day
Study: 1362305
Drug: Flunitrazepam (Rohypnol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (Rohypnol tabl. 1 mg), Tramadol (Tramal caps. 50 mg), Metipranolol (Trimepranol tabl. 10 mg)
Study: 1362305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs with Metipranolol
Study: 22398821
Drug: 70 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 μg/kg ephedrine
Study: 22398821
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg lidocaine
Study: 22398821
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml NaCl 0.9% (placebo)
Study: 17604880
Drug: Extended dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dosing schedule (0, 10, 13, 32 weeks)
Study: 17604880
Drug: Regular dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dosing schedule (0, 3, 6, 32 weeks)
Study: 1967666
Drug: Mitozantrone 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitozantrone 14 mg/m2 intravenously every 3 weeks for 9 weeks
Study: 1967666
Drug: Continue chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue chemotherapy
Study: 1967666
Drug: Stop chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stop chemotherapy
Study: 28177908
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/d and Ezetimibe 10 mg/d